Sodium containing sol-gel derived bioactive glasses and uses thereof including hemostasis
A sol-gel bioactive glass precursor, method for making sol-gel glasses, resultant sol-gel bioactive glasses, and methods of use thereof, which include introducing Na 2 O into the glass network during the sol-gel process through the use of Na-ethoxide, NaCl, or sodium silicate rather than sodium nitrate. Medical and industrial uses of such glasses.
1. A method of making a sol-gel bioactive glass comprising:
mixing a sol-gel bioactive glass precursor including a source of Si, Ca, P, and Na, wherein the source of Na is selected from the group consisting of sodium tert-butoxide, sodium hydroxide, sodium oxalate, sodium sulfate, sodium thiosulfate, sodium dodecyl sulfate, sodium bicarbonate, soda ash, baking soda, sodium silicate, and sodium acetate;
aging the mixture;
drying the mixture to form the sol-gel bioactive glass; and
sintering the sol-gel bioactive glass at 550-650° C. for 15 to 50 hours.
2. The method of claim 1 , wherein said aging is conducted at a temperature of 50-80° C. for 40-70 hours.
3. The method of claim 1 ,
wherein the drying step is at a temperature of 100° C. or lower.
4. The method of claim 1 , further comprising adding a biologically active molecule.
5. The method of claim 1 , wherein the source of Si is selected from the group consisting of tetraethylorthosilicate (TEOS), tetramethylorthosilicate (TMOS), fumed silica, colloidal silica, silica gel, sodium silicate, and silicon tetrachloride.
6. The method of claim 1 , wherein the source of Ca is selected from the group consisting of calcium methoxide, calcium chloride dihydrate, calcium hydroxide, calcium oxalate hydrate, calcium citrate tetrahydrate, calcium sulfate dehydrate, calcium carbonate and, calcium acetate hydrate.
7. The method of claim 5 , wherein the source of Ca is selected from the group consisting of calcium methoxide, calcium chloride dihydrate, calcium hydroxide, calcium oxalate hydrate, calcium citrate tetrahydrate, calcium sulfate dehydrate, calcium carbonate and, calcium acetate hydrate.
8. The method of claim 1 , wherein the source of P is triethylphosphate or sodium hexametaphosphate.
9. The method of claim 1 , wherein the source of Na is present in an amount to provide for 20-30% by weight of Na 2 O in the sol-gel bioactive glass.
10. The method of claim 1 , wherein the source of Si is present in an amount to provide for 20-30% by weight of SiO 2 in the sol-gel bioactive glass.
11. The method of claim 1 , wherein the source of Ca is present in an amount to provide for 20-30% by weight of CaO in the sol-gel bioactive glass.
12. The method of claim 1 , wherein the source of phosphate is triethylphosphate and is present in an amount to provide for 20-30% by weight of P 2 O 5 in the sol-gel bioactive glass.
13. A sol-gel bioactive glass comprising Si, Ca, P, and Na, produced by the method of claim 1 wherein sintering consists of sintering the sol-gel bioactive glass at 550-650° C. for 15-50 hours.
14. The sol-gel bioactive glass of claim 13 , the sol-gel bioactive glass having a porous structure and a significantly higher specific surface area as compared to a melt-derived bioactive glass of the same composition, wherein the sol-gel bioactive glass is strontium free.
15. The sol-gel bioactive glass of claim 13 , wherein Si, Ca, P, and Na are present in their oxide form of SiO 2 , Ca 2 O, P 2 O 5 , and NaO.
16. The sol-gel bioactive glass of claim 15 , further comprising one or more of K, Mg, Zn, B, F, or Ag.
17. The sol-gel bioactive glass of claim 13 , wherein the bioactive sol-gel glass is in a granular form, particulate form, matt form, fiber form, hemostatic sponge form, foam form, paste or putty form, or sphere or bead form, or a combination thereof.
18. The sol-gel bioglass of claim 14 , wherein the significantly higher specific surface area is at least 30 times higher than the melt-derived bioactive glass specific surface area.
19. A method for achieving hemostasis in a patient in need of treatment thereof comprising contacting the patient with the sol-gel bioactive glass produced by the method of claim 1 wherein sintering consists of sintering the sol-gel bioactive glass at 550-650° C. for 15-50 hours.
20. A method of inducing rapid coagulation in a bleeding patient comprising contacting the patient with the sol-gel bioactive glass produced by the method of claim 1 wherein sintering consists of sintering the sol-gel bioactive glass at 550-650° C. for 15-50 hours.
21. A method of treating wounds in a patient comprising contacting the patient with the sol-gel bioactive glass produced by the method of claim 1 wherein sintering consists of sintering the sol-gel bioactive glass at 550-650° C. for 15-50 hours.
22. A method of repairing bone in a patient comprising contacting the bone in need of treatment with the sol-gel bioactive glass prepared by the method of claim 1 wherein sintering consists of sintering the sol-gel bioactive glass at 550-650° C. for 15-50 hours.